---
figid: PMC9526656__ECAM2022-3498310.003
pmcid: PMC9526656
image_filename: ECAM2022-3498310.003.jpg
figure_link: /pmc/articles/PMC9526656/figure/fig3/
number: Figure 3
figure_title: ''
caption: 'Jatrorrhizine attenuates DSS-induced UC in mice. (a) Body weight change
  in each group; (b) Blood in the stool of mice in different groups; (c) DAI score
  in each group; (d, e) Colon length in each group; (f, g) Spleen index and macroscopic
  appearances of the spleen. All data were presented as mean ± SD. (Ctrl: control
  group; DSS: DSS group; 5-ASA: mesalazine group; Jat L: Jatrorrhizine 40 mg/kg dose
  group; Jat M: Jatrorrhizine 80 mg/kg dose group; Jat H: Jatrorrhizine 160 mg/kg
  dose group; ∗p < 0.05 and ∗∗p < 0.01 vs. Control group; ##p < 0.05 and ##p < 0.01
  vs. DSS group).'
article_title: Jatrorrhizine Alleviates DSS-Induced Ulcerative Colitis by Regulating
  the Intestinal Barrier Function and Inhibiting TLR4/MyD88/NF-κB Signaling Pathway.
citation: Shengqi Niu, et al. Evid Based Complement Alternat Med. 2022;2022:3498310.
year: '2022'

doi: 10.1155/2022/3498310
journal_title: 'Evidence-based Complementary and Alternative Medicine : eCAM'
journal_nlm_ta: Evid Based Complement Alternat Med
publisher_name: Hindawi

keywords:
---
